Axoltis Pharma Raises €18 Million To Advance Treatments For ALS, Alzheimer’s, And Parkinson’s

The round was co-led by FIDAT Ventures and Cenitz, with additional support from equity crowdfunding via Capital Cell, business angels, and the Le Cercle de Chiron syndicate. Existing investors including Norfoalk, Fonds Régional Avenir Industrie Auvergne Rhône-Alpes, FaDièse 3, Simba Santé 2, and Axoltis CEO also participated.

“At a time when BioTech funding remains particularly challenging, the success of this round demonstrates that investors believe in our strategy,” said Dr Yann Godfrin, CEO of Axoltis Pharma. “I wish to extend my warmest thanks to the historic investors and newcomers for their trust, support and enthusiasm, and the enlightening discussions we held over the course of their thorough due diligence during the last few months.”

In 2025, several European biotech startups in neurodegenerative and related neurological fields secured new funding, highlighting the context for Axoltis Pharma’s Series A.

Belgium’s Augustine Therapeutics raised €77.7 million for HDAC6-inhibitor therapies, the UK’s TRIMTECH Therapeutics secured €28.6 million for small-molecule degraders targeting protein-aggregate diseases like Alzheimer’s and Huntington’s and France’s EG 427 raised €27 million to advance its gene-regulation platform for chronic neurological disorders.

Read Also - Mirror Security Raises €2.1 Million To Advance FHE-based AI Security In Collaboration With Intel

Combined, these European biotech startups raised around €133 million in 2025, reflecting strong investor interest in innovative approaches to neurology and neurodegeneration.

Axoltis’s Series A reinforces this trend, particularly in France, where EG 427’s funding further signals growing national momentum in CNS-focused biotech.

“This fundraising allows us to maintain our head start in the clinical development of a product that restores the blood-brain barrier. It also means we can continue our discussions with world-class pharmaceutical companies, with a view to a global partnership that would help provide patients with quicker access to this treatment,” adds Dr Godfrin.

Founded in 2016, Axoltis Pharma focuses on developing treatments for neurodegenerative and neurotraumatic diseases with high unmet medical needs, including ALS.

ALS affects around 400,000 people worldwide, primarily targeting motor neurons that control movement. Progressive neuron loss leads to muscle weakness, mobility and speech loss, and, in advanced stages, paralysis and respiratory failure. Most patients survive only two to five years. Currently, 90% of cases are sporadic, and no cure exists.

“Axoltis is developing a breakthrough treatment that could change the lives of millions of patients. If it reaches its full potential, hundreds of investors would also reap significant financial benefits. This translates into a win-win situation for society as a whole,” says Daniel Oliver Uriel, founder and CEO of Capital Cell.

NX210c is an innovative drug candidate targeting neurodegenerative and trauma-related disorders. It promotes blood-brain barrier repair, provides neuroprotection, and enhances neurotransmission, supporting overall brain health and recovery.

“The enthusiasm, perseverance and resilience demonstrated by the Axoltis team over the last few months are exceptional in the current financial climate,” said Dr Gilles Avenard, chairman of the Axoltis supervisory board.

The €18 million Series A was raised in two tranches, with the second contingent on results from the ongoing SEALS phase 2 trial. Launched in late 2024, SEALS evaluates NX210c’s efficacy and tolerability in 82 ALS patients across 16 sites, also assessing its ability to repair the blood-brain barrier a key factor in ALS, Alzheimer’s, MS, and Parkinson’s.

The final patient was enrolled in mid-November, with results expected in Q2 2026. Funds will also support research into other neurological indications where NX210c’s blood-brain barrier repair properties could have significant therapeutic impact.

“Axoltis Pharma combines a high-performance team, a distinctive technology and remarkable development potential; we are delighted to be working alongside the company from now on,” said Frédéric Picq, co-founder and partner at Cenitz.

About Axoltis Pharma

Axoltis Pharma is developing NX210c a pioneering treatment for ALS, a devastating neurodegenerative disease. NX210c restores the blood-brain barrier, holds orphan drug designation in the US and EU and is in Phase 2 trials with results expected April 2026. It targets a high unmet medical need with strong safety data.